Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 07, 2022 07:00 ET | Source: Tango Therapeutics, Inc.

Tango Therapeutics to Participate in Upcoming Investor Conferences

BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision...
October 19, 2022 07:00 ET | Source: Tango Therapeutics, Inc.

Tango Therapeutics Announces Presentation of Preclinical Data on PRMT5 Inhibitors TNG908 and TNG462 in Three Abstracts Accepted at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

BOSTON, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines,...
October 05, 2022 08:10 ET | Source: Tango Therapeutics, Inc.

Tango Therapeutics Announces Presentation of Preclinical Data on TNG260 and Discovery Platform Advances at SITC 37th Annual Meeting

CAMBRIDGE, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer...
September 06, 2022 07:00 ET | Source: Tango Therapeutics, Inc.

Tango Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer...
August 10, 2022 07:00 ET | Source: Tango Therapeutics, Inc.

Tango Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights

– Patients with MTAP-deleted solid tumors being actively enrolled in ongoing Phase 1/2 trial of TNG908, an MTA-cooperative PRMT5 inhibitor – – Received Orphan Drug Designation in US for the treatment...
August 02, 2022 07:00 ET | Source: Tango Therapeutics, Inc.

Tango Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference

CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer...
June 27, 2022 07:00 ET | Source: Tango Therapeutics, Inc.

Tango Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes

CAMBRIDGE, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer...
June 08, 2022 07:00 ET | Source: Tango Therapeutics, Inc.

Tango Therapeutics to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference

CAMBRIDGE, Mass., June 08, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer...
May 11, 2022 07:00 ET | Source: Tango Therapeutics, Inc.

Tango Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights

– Phase 1/2 trial of TNG908, a synthetic lethal PRMT5 inhibitor, for the treatment of MTAP-deleted solid tumors open for enrollment – – Declared TNG462 as a development candidate - a...
May 09, 2022 07:00 ET | Source: Tango Therapeutics, Inc.

Tango Therapeutics to Participate in the Guggenheim Synthetic Lethality Day 2022

CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer...